CSL Behring
BiotechMelbourne, Victoria, Australia · Est. 1916 · 27,000 employees
CSL Behring is a biopharmaceutical company specializing in plasma-derived and recombinant protein therapies for immunology, hemostasis, critical care, and immunodeficiency conditions.
12
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
16
Indications↗
Distinct diseases across all programs
143
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
12 drugs in development
Approved3
Phase 34
Phase 27
Phase 11
Preclinical1
By Therapeutic Area
top 6
Hematology
425%
Immunology
319%
Rare Disease
213%
Cardiovascular
16%
Neurology
16%
Respiratory
16%
R&D Momentum
58/100
Pipeline Velocity
27/100
Trial Completion Rate
85/100
Pipeline Concentration
15/100
Pipeline Freshness
77/100
Strategic Signals
- ↗Active in Rare Disease but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Jun 27, 2026TrialA Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
Apr 15, 2026TrialPhase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
Mar 12, 2026TrialHOPE-B Extension: Etranacogene Dezaparvovec 5-Year
Mar 8, 2026TrialETERNITY: Etranacogene Dezaparvovec in Hemophilia B
Feb 2, 2026TrialSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Sep 15, 2025TrialEfficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
Sep 3, 2025TrialDose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
4 more events
Jul 15, 2025TrialAn Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
Jul 10, 2025TrialSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Jun 16, 2025FDAAndembry — ANDEMBRY
May 27, 2025TrialEffect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults
Details
Company Info
Company Overview
$145.0B
Mkt Cap
$13.5B
Revenue
—
Cash
CEOPaul Perreault
Founded1916
Employees27,000
HQMelbourne, Victoria, Australia
Websitecslbehring.com
LinkedInCompany Page
Therapeutic Focus
ImmunologyHemophiliaImmunodeficiencyCritical Care
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Metabolic & Endocrine
Respiratory
Cardiovascular
Thrombocytopenic Purpura
IgPro10Approved
Hematology
Hemophilia B
factor ixPhase 3
Sickle Cell Disease
AnumigilimabPhase 2
CSL889Phase 2
Immunology
Metabolic & Endocrine
Neurology
Rare Disease
Cystic Fibrosis
CSL787Phase 2
Hereditary Angioedema
AndembryApproved
Respiratory
Unknown / Other
Showing 15 of 19 programs
Regulatory
Regulatory Timeline
20251 event
FDAJun 16
Andembry — ANDEMBRY
Application BLA761367 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)